Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
The goal of this prospective, single-center, open-label, dose-escalation study is to evaluate the safety, tolerability, and preliminary efficacy of CD-001 in patients with advanced head and neck cancers who have experienced disease progression (PD) or intolerance to standard systemic therapy (or lack thereof). The main question\[s\] it aims to answer:
* What is the safety and tolerability profile of CD-001 across escalating doses?
* What is the preliminary efficacy of CD-001 in this patient population?